Two-Year Treatment Persistence of Guselkumab vs Other Biologics in Plaque Psoriasis Patients.
In both biologic-naïve and biologic-experienced cohorts in this real-world study, average treatment persistence was significantly longer for guselkumab compared to adalimumab and secukinumab and numerically longer compared to ixekizumab.
Authors
- Katelyn Rowland
- Olivia Choi
- Elizabeth R. Lesser (ORCID: https://orcid.org/0000-0001-9414-7107)
- Rachel E. Teneralli (ORCID: https://orcid.org/0000-0003-4340-9001)
- Timothy Fitzgerald (ORCID: https://orcid.org/0000-0003-3441-1708)
- Daphne Chan
- Michael C. Cameron (ORCID: https://orcid.org/0000-0002-0622-2312)
- Mark Lebwohl (ORCID: https://orcid.org/0000-0002-4705-5303)
- Jud C. Janak (ORCID: https://orcid.org/0009-0001-5620-5211)
- Bruce E Strober (ORCID: https://orcid.org/0000-0002-8394-2057)
- Maya Marchese (ORCID: https://orcid.org/0000-0003-1915-5793)
Publication Details
- Journal
- PubMed
- Published
- 2025-08-01
- Primary Topic
- Psoriasis: Treatment and Pathogenesis
- Type
- article
- Field-Weighted Citation Impact
- 0.00